At the end of 2019, the Zur Rose Group and medpex online pharmacy vendors agreed to settle the 2019 and 2020 earn-out components that form part of the purchase price by making a one-off payment of the amount calculated in the preliminary financial statements for 2019. Since the acquisition, medpex’s owners have effectively pushed the company forward and achieved the negotiated growth targets. Medpex holds the best-in-class online marketing and technological capabilities and is a perfect addition to the current strategy of expanding market share on the German market.
Through finishing early sales, the Zur Rose Group plans to use the founders ‘ experience for the whole sector of Germany as quickly as possible. Therefore, they carry on leadership positions in the division of Germany. To connect them to the Zur Rose Group, they participate significantly in a management share program and will increase their existing holdings significantly.
The Swiss Zur Rose Company is the first e-commerce company in Europe and one of Switzerland’s leading medical wholesalers. It offers high-quality, healthy and cost-effective prescription treatment with its business model, thereby helping to reduce healthcare costs.
It is also distinguished by the ongoing development of automated product management services and actively promotes its role as a robust, interconnected cross-service healthcare network. The creation of added value and a strong patient orientation make the Group a key strategic partner for service providers, payers and industry.
Its large brands, including Germany’s best-known pharmacy chain DocMorris, the Zur Rose Group is active globally. The company employs more than 1,300 people at different locations and generated a turnover of CHF 1,207 million in the fiscal year 2018. Zur Rose Group AG’s shares are listed on the SIX Swiss Exchange